ASCO 2019: Scientific Knowledge Exchange on Immunotherapy in Melanoma
In this year’s Scientific Knowledge Exchange, Prof. Dr. Reinhard Dummer, University Hospital of Zurich, and Prof. Dr. Olivier Michielin, University Hospital of Lausanne, discuss ASCO 2019’s news in melanoma research and therapy.
Video Contents00:48 Dramatic increase in knowledge about basic principles of tumor biology that are now routinely monitored 01:37 Role of IL-6 and CRP associated with poor outcomes in several cancer types 02:44 Tumour mutational burden in context with tumor inflammation and cancer types 05:30 Encouraging results for immunotherapy on brain metastases of melanoma 06:40 No benefit of whole brain radiation after stereotactic radiosurgery 07:27 Combination of Immunotherapy and targeted therapies – the COMBI-i study, and sequential therapy vs. triple therapy 10:15 Adjuvant therapy is changing the population of stage IV melanoma patients, need for guidelines 10:56 Oncolytic viruses in the neoadjuvant setting – first prospective randomized study 12:30 Agonistic checkpoints to stimulate GITR: GITR/PD-1 combination 13:40 Why IDO1 remains an interesting target 14:52 Promising options for patients with advanced squamous cell carcinoma of the skin 15:44 Studies on what needs to be done when anti-PD-1 fails 16:14 Emergence of real world data for IO
Source: ASCO 2019
The following abstracts are discussed in this SKE:
#9511 Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy. https://meetinglibrary.asco.org/record/174187/abstract
#100 Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.
#9501 Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). https://meetinglibrary.asco.org/record/173427/abstract
#9500 Fogarty G et al. Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs). http://meetinglibrary.asco.org/content/258029-239
#9551 Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without ipilimumab (IPI) versus IPI: CheckMate 067 4-year data. https://meetinglibrary.asco.org/record/176201/abstract
#9531 The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
#9502 Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). https://meetinglibrary.asco.org/record/159076/abstract
#9520 One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL).
#9503 Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). https://meetinglibrary.asco.org/record/173444/abstract
#9509 Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors.
9522# Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).
#9505 Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry.
More from this topic:
ASCO 2019: Durable responses in patients with melanoma brain metastases with nivolumab/ipilimumab
11. 06. 2019
ASCO 2019: Pembrolizumab facilitates previously unmet 5-year-overall survival for NSCLC
06. 06. 2019